Harnessing the Immune System to Fight Cancer

Our mission, our ambition. Cancer is a extraordinary complex disease. We are learning that only a massive attack can result in better therapeutic outcomes. At Takis we are developing ground-breaking innovative vaccines based on cutting-edge technologies. Our genetic vectors have the potential to activate a potent, pleiotropic immune response against cancer and other diseases. As scientists, we fully recognize that only a deep and evolving knowledge of cancer biology, immunology and new target discovery will help finding new effective therapies. And we are aware that combination therapies are key to success.

Cancer Immunotherapy is currently facing a spectacular renaissance and we strongly believe that this approach will become an established therapeutic modality for the treatment of cancer within the next decade. We are proud to contribute to this challenging objective.

We invite you to join us in this revolutionary field and offer new perspectives to cancer patients.

Luigi Aurisicchio, PhD
CEO/CSO

Takis Biotech

Takis Services